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Introduction: The aim of our study was to evaluate the clinical impact of the administration of intravenous steroids,
alone or in conjunction with drotrecogin-alfa (activated) (DrotAA), on the outcomes in septic shock patients.
Methods: We performed a sub-study of the PROWESS-Shock trial (septic shock patients who received fluids and
vasopressors above a predefined threshold for at least 4 hours were randomized to receive either DrotAA or
placebo for 96 hours). A propensity score for the administration of intravenous steroids for septic shock at baseline
was constructed using multivariable logistic regression. Cox proportional hazards model using inverse probability
of treatment weighting of the propensity score was used to estimate the effect of intravenous steroids, alone or in
conjunction with DrotAA, on 28-day and 90-day all-cause mortality.
Results: A total of 1695 patients were enrolled of which 49.5% received intravenous steroids for treatment of
septic shock at baseline (DrotAA + steroids N = 436; DrotAA + no steroids N = 414; placebo + steroids N = 403;
placebo + no steroids N = 442). The propensity weighted risk of 28-day as well as 90-day mortality in those treated
vs. those not treated with steroids did not differ among those randomized to DrotAA vs. placebo (interaction
p-value = 0.38 and p = 0.27, respectively) nor was a difference detected within each randomized treatment.
Similarly, the course of vasopressor use and cardiovascular SOFA did not appear to be influenced by steroid
therapy. In patients with lung infection (N = 744), abdominal infection (N = 510), Gram-positive sepsis (N = 420)
and Gram-negative sepsis (N = 461), the propensity weighted risk of 28-day as well as 90-day mortality in those
treated vs. those not treated with steroids did not differ among those randomized to DrotAA vs. placebo nor was
a difference detected within each randomized treatment.
Conclusions: In the present study of septic shock patients, after adjustment for treatment selection bias, we were
unable to find noticeable positive impact from intravenous steroids for treatment of septic shock at baseline either
in patients randomized for DrotAA or placebo.
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Severe sepsis and septic shock are amongst the major
causes of intensive care admissions [1,2] and despite the
recent improvements in clinical outcomes, mortality rates
are still elevated, varying from 20 to 35% [3-5]. Improved
outcome is mainly ascribed to earlier identification and
improvements in the process of care of sepsis rather than
specific pharmacologic interventions [6-9].
In recent years, the uses of corticosteroids and to a lesser
degree drotrecogin-alfa activated (DrotAA) have been the
cornerstones of adjunctive pharmacologic therapy for severe
sepsis and septic shock [10-13]. However, the results of the
more recent clinical trials have failed to demonstrate clinical
benefits from either intervention [14-16]. In addition, sup-
porters of the use of corticosteroids for septic shock claim
that the CORTICUS study results had limited external valid-
ity due to the fact that it excluded patients whose clinicians
decided to treat with corticosteroids. This a priori decision
potentially biased the study by enroling patients with either
lower severity of illness or those thought to receive less
benefit [17,18]. Furthermore, although there are potential
synergies in the concomitant use of corticosteroids and Dro-
tAA, only one recent study evaluated this issue, and it was
limited by the discontinuation of the DrotAA arm when the
drug was withdrawn from the market [16].
In the present study, we have evaluated the clinical im-
pact of corticosteroids alone or in conjunction with Dro-
tAA in patients with septic shock by analyzing data from
the PROWESS-Shock trial [15]. We hypothesized that
the patients who received corticosteroids as part of usual
care will improve their outcomes after adjustment for
baseline imbalances.
Materials and methods
Study design and setting
Patients diagnosed with septic shock were randomly
assigned to receive either DrotAA (24 μg/kg/hour) or pla-
cebo administered intravenously for 96 hours [15]. All de-
tails of the PROWESS-Shock trial and its design have been
reported elsewhere (NCT00604214) [15]. The PROWESS-
Shock trial was approved by the research ethics boards of
all participating institutions. Patients, next of kin, or surro-
gate decision-makers gave written informed consent in ac-
cordance with local requirements. The trial was conducted
in accordance with the Declaration of Helsinki. The present
analysis was proposed and approved by the Steering Com-
mittee of the PROWESS-Shock trial, which in addition
considered there was no need for further ethical approval.
The concomitant use of steroids as adjunctive treatment
of septic shock, according to the recommendations at the
time [13], was at the discretion of the attending physician
and was not required by the study protocol. The question
used in the case report form to collect data on steroid use
was the following: “Was the subject treated with anyintravenous steroid therapy for septic shock during the pre-
treatment period (before study drug infusion)?” No add-
itional information on steroid adjunctive therapy use was
recorded, namely type of steroid, dose, type of infusion
(intermittent or continuous) or duration of therapy.
For the present analysis we divided the two arms of the
trial, the DrotAA and the placebo arms, into four groups
according to the prescription of intravenous steroid ther-
apy for septic shock. These were: 1) patients receiving ste-
roids at baseline and randomized to receive DrotAA; 2)
patients not receiving steroids at baseline and randomized
to receive DrotAA; 3) patients receiving steroids at base-
line and randomized to receive placebo, and 4) patients
not receiving steroids at baseline and randomized to re-
ceive placebo. Study outcome was all-cause mortality at
28 days and at 90 days. In addition, we assessed the course
of organ failure, in particular cardiovascular sequential
organ failure assessment (SOFA) score, as well as the mor-
tality due to secondary refractory septic shock.
Statistical analysis
Baseline characteristics of patients were compared by
treatment strategy using the Kruskal-Wallis test for con-
tinuous variables and Pearson Chi-square test for categor-
ical variables. Kaplan-Meier estimates and survival curves
for 28-day and 90-day all-cause mortality amongst all pa-
tients were weighted by the inverse probability of receiv-
ing steroid therapy at baseline, using a propensity score.
Estimates of the hazard ratios (95% CI) of all-cause mor-
tality for all patients and for patients within each of the fol-
lowing subgroups were displayed in a forest plot on the
log-odds scale in: 1) patients with lung infection; 2) patients
with abdominal infection; 3) patients with Gram-positive
sepsis, and 4) patients with Gram-negative sepsis. The haz-
ard ratio (95% CIs) estimates and the P-values for the inter-
action terms of randomized treatment*baseline steroid use
were obtained using inverse probability-weighted Cox pro-
portional hazards models [19].
A propensity score (that is, probability of receiving
intravenous steroid therapy for septic shock at baseline)
was calculated using a multivariable logistic regression
model after adjusting for clinically relevant patient char-
acteristics at baseline. The following variables were se-
lected to be included in the propensity model: age;
gender; baseline acute physiology and chronic health
evaluation (APACHE) II score; baseline total SOFA
score; time between first vasopressor and study drug in-
fusion (hours); number of baseline organ dysfunctions
(1 to 5); baseline lactate concentration (mmol/L); IV
fluids in 24 hours before start of vasopressors (mL);
intravenous (IV) fluids from the start of vasopressor to
the start of study drug infusion (mL); baseline vasopres-
sor score (a dimensionless variable calculated as follows:
dopamine dose (mcg/kg/min) × 1) + (dobutamine dose
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100) + (norepinephrine dose (mcg/kg/min) × 100) + (phenyl-
ephrine dose (mcg/kg/min) × 100 + (vasopressin dose (mcg/
kg/min) × 100) [20-22]; whether or not the patient had an
abdominal infection, and whether or not the patient had a
lung infection. The adequacy of the propensity model was
assessed by checking the distribution of the propensity
scores by treatment for a reasonable overlap and the pre-
and post-inverse probability of treatment-weighting balance
of the covariates [23].
Missing data were handled using the Markov chain
Monte Carlo full-imputation strategy with a single imput-
ation. After imputation, continuous variables were evalu-
ated for linearity and cubic splines utilized, if necessary.
Descriptive statistics for change in vasopressor-free days
from day 1 to day 6 and change in cardiovascular SOFA
from baseline to day 6 were provided. No statistical testing
was performed to detect differences in these outcomes
across treatment strategy because no information was ob-
tained during the trial on when steroid treatment began
post-baseline. P-values <0.05 were used to determine stat-
istical significance. All analyses were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
In the PROWESS-Shock trial, 49.5% of patients received
intravenous steroids for treatment of septic shock at
baseline in the pretreatment period before DrotAA infu-
sion (steroid use at baseline + DrotAA, n = 436; no ster-
oid use at baseline + DrotAA, n = 414; steroid use at
baseline + placebo, n = 403; no steroid use at baseline +
placebo, n = 442; total n = 1,695. There was a difference
of two patients from the enroled patients in the
PROWESS-Shock trial, one patient was randomized
without prior consent and another without baseline
steroid usage information) [15].
Table 1 presents the baseline characteristics of the pa-
tients at trial inclusion according to the four defined
groups. Patients who received intravenous steroids had
a significantly higher APACHE II score, total SOFA
score, need for mechanical ventilation and incidence of
acute respiratory distress syndrome, and higher need for
renal replacement therapy than patients who did not re-
ceive intravenous steroids in both arms of the trial. In
addition, patients on steroids had significantly greater
need of vasopressors, as indicated by a higher vasopres-
sor score. Patients treated with steroids received a sig-
nificantly lower volume of fluids in the 24 hours before
start of vasopressors, but from the start of vasopressors
to the start of the study drug (either DrotAA or placebo)
they received a significantly greater volume. Finally, the
median total amount of fluid received by each of the
four groups was comparable (DrotAA with and without
steroids, 8,130 and 8,238 mL, respectively; placebo withand without steroids, 8,000 and 8,065 mL, respectively,
P = 0.69).
Impact of steroids in septic shock mortality
The propensity-weighted risk of 28-day and 90-day all-
cause mortality in those treated with steroids versus
those not treated with steroids at baseline did not differ
among those randomized to DrotAA versus placebo
(interaction P-value = 0.38 and P = 0.27, respectively) nor
was a difference detected within each randomized treat-
ment (Table 2). Figure 1 presents the weighted Kaplan-
Meier 90-day mortality according to randomized treat-
ment (DrotAA versus placebo) and baseline steroid use
for septic shock treatment.
In patients with lung infection (n = 744), patients
with abdominal infection (n = 510), patients with Gram-
positive sepsis (n = 420) and patients with Gram-negative
sepsis (n = 461), the propensity-weighted hazard of 28-day
as well as 90-day mortality in those treated with steroids
versus those not treated with steroids did not differ for
those randomized to DrotAA versus placebo nor was a
difference detected within each randomized treatment
(Figure 2).
Impact of steroids in the course of septic shock
We described the effect of intravenous steroids in the
weaning from vasopressor as expressed by propensity-
weighted vasopressor-free days from day 1 to day 6 as
well as propensity-weighted change of cardiovascular
SOFA from baseline to day 6 (Table 3). Septic shock pa-
tients randomized to DrotAA or placebo who received
steroids seemed to present a similar course of vasopres-
sor use as those without steroid therapy. Likewise, there
appeared to be a similar decrease in cardiovascular
SOFA between those treated with steroids and those not
treated with steroids, regardless of which randomized
treatment was assigned, DrotAA or placebo. Finally, 90-
day mortality (propensity-weighted) by refractory septic
shock in patients randomized to DrotAA or placebo
who received steroids was similar to those without ster-
oid therapy (25.6, 28.8, 25.2 and 28.4%, respectively).
Discussion
We found no benefits from the use of intravenous ste-
roids for treatment of septic shock at baseline either in
patients randomized to DrotAA or placebo. In addition,
we observed that intravenous steroids did not seem to
influence the clinical course of septic shock, expressed
by the cardiovascular SOFA, vasopressor-free days, and
death from refractory shock.
The role of steroids as an adjunctive therapy in the
treatment of septic shock has been a controversial issue
for many decades [24]. A large meta-analysis including
17 randomized controlled trials (RCT) and 3 quasi-RCTs










Number 436 414 403 442
Age, years 0.1007
Median (25th, 75th percentile) 64.4 (52.5, 74.2) 66.2 (55.4, 76.0) 66.2 (54.5, 76.6) 63.6 (51.4, 75.2)
Female, n/total (%) 190/436 (43.6%) 169/414 (40.8%) 185/403 (45.9%) 194/442 (43.9%) 0.5350
Prior or preexisting conditions
Alcohol dependence 58/436 (13.3%) 59/414 (14.3%) 53/403 (13.2%) 61/442 (13.8%) 0.9604
Chronic liver disease 18/436 (4.1%) 11/414 (2.7%) 12/403 (3.0%) 17/442 (3.8%) 0.6109
Chronic obstructive airways disease 69/436 (15.8%) 59/414 (14.3%) 66/403 (16.4%) 65/442 (14.7%) 0.8084
Chronic renal disease 49/436 (11.2%) 35/414 (8.5%) 30/403 (7.4%) 37/442 (8.4%) 0.2380
Congestive heart failure 27/436 (6.2%) 21/414 (5.1%) 22/403 (5.5%) 23/442 (5.2%) 0.8837
Coronary artery disease 57/436 (13.1%) 55/414 (13.3%) 37/403 (9.2%) 49/442 (11.1%) 0.2024
Diabetes mellitus 100/436 (22.9%) 89/414 (21.5%) 90/403 (22.3%) 126/442 (28.5%) 0.0618
Hypertension 190/436 (43.6%) 191/414 (46.1%) 201/403 (49.9%) 201/442 (45.5%) 0.3341
Immunodeficiency 40/436 (9.2%) 11/414 (2.7%) 41/403 (10.2%) 18/442 (4.1%) <0.0001
Malignancy (cancer) 81/436 (18.6%) 64/414 (15.5%) 83/403 (20.6%) 64/442 (14.5%) 0.0629
Pancreatitis 18/436 (4.1%) 12/414 (2.9%) 13/403 (3.2%) 12/442 (2.7%) 0.6509
Stroke 25/436 (5.7%) 23/414 (5.6%) 19/403 (4.7%) 25/442 (5.7%) 0.9048
Positive blood culture 143/436 (32.8%) 127/414 (30.7%) 122/403 (30.3%) 117/442 (26.5%) 0.2262
Source control of infectionb 138/151 (91.4%) 137/152 (90.1%) 133/149 (89.3%) 131/146 (89.7%) 0.9355
Number of baseline organ dysfunctions <0.0001
1 8/436 (1.8%) 10/414 (2.4%) 6/403 (1.5%) 17/442 (3.8%)
2 41/436 (9.4%) 74/414 (17.9%) 35/403 (8.7%) 77/442 (17.4%)
3 133/436 (30.5%) 144/414 (34.8%) 132/403 (32.8%) 162/442 (36.7%)
4 185/436 (42.4%) 142/414 (34.3%) 162/403 (40.2%) 154/442 (34.8%)
5 69/436 (15.8%) 44/414 (10.6%) 68/403 (16.9%) 32/442 (7.2%)
Time from start of vasopressor to infusion start, hours 0.1390
Median (25th, 75th percentile) 19.1 (13.0, 22.7) 17.0 (13.0, 21.5) 18.2 (12.8, 22.0) 18.0 (11.6, 22.2)
Apache II score <0.0001
Median (25th, 75th percentile) 25.0 (20.0, 31.0) 24.0 (19.0, 30.0) 26.0 (21.0, 32.0) 23.0 (18.0, 29.0)
Recent surgery 159/436 (36.5%) 157/414 (37.9%) 143/403 (35.5%) 165/442 (37.3%) 0.8968









Table 1 Baseline characteristics by steroid use for treatment of septic shock at baseline and randomized treatment of all patients (Continued)
Renal replacement therapy 88/432 (20.4%) 32/413 (7.7%) 80/402 (19.9%) 27/442 (6.1%) <0.0001
Acute respiratory distress syndrome 144/436 (33.0%) 80/414 (19.3%) 123/403 (30.5%) 114/442 (25.8%) <0.0001
Intravenous fluids from start of vasopressor to start of study drug, mL 0.0093
Median (25th, 75th percentile) 4858 (3210, 7840) 4458 (2746, 6865) 4635 (2904, 7508) 4222 (2755, 6460)
Intravenous fluids in 24 hours before start of vasopressors, mL <0.0001
Median (25th, 75th percentile) 2902 (1850, 4384) 3250 (2197, 5100) 2850 (1600, 4350) 3250 (2105, 5000)
Vasopressor score <0.0001
Median (25th, 75th percentile) 50.0 (23.0, 98.0) 27.0 (12.2, 46.4) 50.0 (22.9, 90.9) 21.9 (12.6, 44.4)
Total sequential organ failure assessment <0.0001
Median (25th, 75th percentile) 11.0 (9.0, 13.0) 10.0 (8.0, 12.0) 11.0 (9.0, 13.0) 10.0 (8.0, 12.0)
Lactate, mmol/L <0.0001
Median (25th, 75th percentile) 3.0 (1.9, 4.8) 2.2 (1.4, 3.3) 3.1 (2.0, 5.1) 2.1 (1.4, 3.3)










Table 2 Survival analysis of 28-day and 90-day all-cause mortality (propensity-weighted), all patients, by steroid use at
















Estimate 24.8% 29.5% 0.826 23.5% 23.3% 1.001 0.3764
95% CI 20.6, 29.7 25.1, 34.5 0.616, 1.107 19.2, 28.6 19.4, 27.8 0.735, 1.364
Day 90
Estimate 34.1% 37.9% 0.874 32.8% 30.6% 1.074 0.2743
95% CI 29.4, 39.3 33.1, 43.0 0.678, 1.127 27.9, 38.4 26.2, 35.4 0.822, 1.403
aInverse proportional weighted Kaplan-Meier rate and associated 95% CI. bHazard ratios of steroid versus no steroid use and randomized treatment*steroid use
interaction P-value obtained using inverse proportional weighted Cox proportional hazards model. Observations weighted by the inverse probability of being
prescribed a steroid therapy at baseline using a propensity model including the following variables: age, gender, baseline acute physiology and chronic health
evaluation II score, baseline total sequential organ failure assessment, time between first vasopressor and study drug infusion (hours), number of baseline organ
dysfunctions (1 to 5), baseline lactate concentration (mmol/L), intravenous (IV) fluids in 24 hours before start of vasopressors (mL), IV fluids from the start of
vasopressor to the start of study drug infusion (mL), and baseline vasopressor score. DrotAA, drotrecogin-alfa activated.
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corticosteroid therapy in septic shock patients [25].
However, the analysis of the impact of low-dose cortico-
steroids in septic shock mortality assessed in large
clinical registries showed little or no effect [7] or a sig-
nificant increase in mortality [26], even after adjusting
for clinical severity. Similarly, a recent meta-analysis
found no statistically significant difference in mortality
(relative risk 1.00, 95% CI, 0.84, 1.18) [27]. Recently, Del-
linger and coworkers [8] found that hydrocortisone
failed to show any benefit on outcome (relative risk
1.06) if the meta-analysis included only the six high-level
RCTs with low risk of bias [11,14,28-31] and excluded
studies with placebo mortality >60%.Figure 1 Propensity-weighted Kaplan-Meier 90-day all-cause mortality acco
steroid use for septic shock treatment. P = 0.27. DrotAA, drotrecogin-alfa acIn the midst of these conflicting results, two recent obser-
vational studies were published [32,33] that brought a little
light to these issues [34,35]. The first study from Katsenos
et al. [32], showed a potential mortality benefit from early
initiation of steroids (in the first 9 hours after vasopressors).
However, these results are compromised by several limita-
tions, namely the small and asymmetric sample size, the
fact that the impact of steroid therapy was not adjusted for
clinical severity nor organ dysfunction, and the very high
mortality rate at 28 days (almost 70% in patients with late
steroid initiation) [34]. The study from Funk et al. [33] was
a large retrospective multicenter propensity-matched co-
hort study that showed no benefit from low-dose cortico-
steroids in septic shock patients either in 30-day mortalityrding to randomized treatment (DrotAA versus placebo) and baseline
tivated.
Prowess-Shock: Weighted Hazard Ratio of Steroid vs. No Steroid Use Within Treatment
Outcome = 28-day Mortality
X-axis is on the log scale
P-value
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Figure 2 Impact of steroids in septic shock mortality; 28-day and 90-day all-cause mortality (propensity-weighted) for PROWESS-Shock patients
and subgroups (abdominal infection, lung infection, Gram-positive infection and Gram-negative infection). D28, day 28; D90, day 90; HR, hazard
ratio; DrotAA, drotrecogin-alfa activated.
Póvoa et al. Critical Care  (2015) 19:193 Page 7 of 10or vasopressor dependence. However, in those with higher
severity, with APACHE II ≥30, there might be a benefit,
whereas in the lower clinical-severity quartiles there mightbe potential harm. Similarly, this study has also several limi-
tations, in particular the very long period of patient inclu-
sion (11 years) during which a marked change in mortality










Change in cardiovascular sequential organ failure assessment
Mean (SD) −2.8 (1.6) −2.7 (1.6) −2.8 (1.6) −2.9 (1.6)
Median (25th, 75th percentile) −4 (−4,-1) −4 (−4,-1) −4 (−4,-1) −4 (−4,-2)
Minimum, maximum −4, 1 −4, 1 −4, 1 −4, 1
Vasopressor-free days
Mean (SD) 2.5 (2.0) 2.7 (2.1) 2.4 (2.0) 2.9 (2.0)
Median (25th, 75th percentile) 3 (0,4) 3 (0,5) 3 (0,4) 4 (1,5)
Minimum, maximum 0, 6 0, 6 0, 6 0, 6
DrotAA, drotrecogin-alfa activated.
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clude variables associated with shock severity, namely the
SOFA score or the number and dose of vasopressors. Fi-
nally, almost 16% of low-dose corticosteroids given to septic
shock patients did not have APACHE II score recorded.
Conversely, when the two largest RCTs [11,14] of low-
dose corticosteroids were analyzed, one (n = 300) suggests
a marked positive impact of steroids on mortality in septic
shock only in the patients who did not respond to the
short corticotropin test, whereas the second (n = 499)
found no beneficial effect irrespective of the response to
the short corticotropin test [14].
However, these two RCTs are not totally comparable.
Septic shock patients in the positive trial had a higher
Simplified Acute Physiology Score II at baseline, were un-
responsive to vasopressors, were all under mechanical
ventilation (compared to 86% in CORTICUS and 82% in
PROWESS-Shock) and there was a much higher rate of
death at 28 days in the placebo group (61% compared with
32% in the CORTICUS trial). The enrolment of patients
in the positive trial was allowed only within 8 hours after
fulfilling inclusion criteria, as compared with a 72-hour
window in the negative trial. Therefore, some authors per-
ceive that results of the negative trial represent the
randomization of patients whose clinicians decided not to
treat with corticosteroids, that is, those with less severe
clinical presentation [17,18]. Taken together, these find-
ings might suggest a potential benefit of steroids for the
most severe cases at the earliest stages of septic shock.
In the present analysis of PROWESS-Shock trial, we con-
firmed that steroid use in usual care was indeed reserved
for more critically ill individuals. However, we could not
confirm such benefit from this practice, even when steroids
were administered early in the course of shock, with or
without concomitant DrotAA. The same was true in the
different subgroup analyses, namely of patients with lung
infection, abdominal infection, Gram-positive infection or
Gram-negative infection.Both trials that assessed the efficacy of DrotAA [10,15]
allowed the use of intravenous steroids at the discretion
of the attending physician. In line with the original rec-
ommendations of the Surviving Sepsis Campaign [12], as
well as the 2008 revision [13], the administration of
intravenous steroids for treatment of septic shock was
recommended and as a result its prescription increased
from 36.0% in the original PROWESS trial to 49.5% in
the PROWESS-Shock trial.
The potential synergies in the concomitant use of corti-
costeroids and DrotAA were evaluated in only one recent
study, and this analysis was limited by the discontinuation
of the DrotAA [16]. However, the authors found no signifi-
cant interaction between corticosteroids and DrotAA (P =
0.47). Similarly, in our analysis we were unable to find any
significant interaction between these two drugs among the
total patient group, or in the different subgroups, namely of
patients with lung infection, abdominal infection, Gram-
positive or Gram-negative sepsis.
In addition, we were unable to demonstrate any significant
improvement in hemodynamic stability associated with the
use of corticosteroids [11,14]. Nonetheless we could not
evaluate the response to the short corticotropin test, as it
was not routinely performed and if performed those data
were not collected in the PROWESS-Shock trial. However,
in the past decade a significant amount of data have ques-
tioned the validity of the results of such a test in this setting
[36,37]. First, there is a great variability of cortisol measure-
ments observed between different methods and laboratories
[36]. Also, the relationship between total and free cortisol
levels had also been shown to be poor [38]. Finally, it has
been shown in critically ill patients that cortisol production
was 83% higher and cortisol clearance was 50% lower in
comparison to matched controls. These factors account for
a 3.5 times greater cortisol level in these patients [39].
In our study there are also several limitations that need
to be acknowledged. The present study was not designed
to stratify by the use of corticosteroids a priori and
Póvoa et al. Critical Care  (2015) 19:193 Page 9 of 10unmeasured confounders may have been missed or incom-
pletely accounted for in our propensity adjustments.
Enroled patients must have survived the initial resuscitation
period to be randomized, which was on average 17 hours
from the onset of vasopressor use [15]. As a result only sep-
tic shock patients that survived to that time point were ana-
lyzed, excluding very sick septic shock patients. As a result
patients with early refractory shock and early deaths during
this period were not included. We were unable to analyze
the type, the dose of corticosteroid drug administered and
the duration of steroid therapy, as these data were not col-
lected. Only the prescription of intravenous steroid therapy
for septic shock during the pretreatment period (before
study drug infusion) was recorded. In addition, data on eto-
midate and fludrocortisone prescription was not collected
in the PROWESS-Shock database. Similarly the steroid-
related complications namely myopathy, nosocomial infec-
tions, and metabolic alteration were not fully available.
However, if we consider endpoints such as all-cause mortal-
ity and duration of mechanical ventilation as surrogates for
these complications, we did not find significant differences
among the groups. Nonetheless, we acknowledge that these
safety issues deserve in-depth analysis with specific and ro-
bust data collection in future studies.
The present study does have several strengths. Our ana-
lyses utilized data from a large multicenter and well-
conducted RCT collected during a 25-month period and
with a 90-day follow up. In addition, the inverse probabil-
ity of treatment weighting using the propensity score to
perform our analysis balances measured covariates be-
tween those prescribed steroids and those not prescribed
steroids [23].
Conclusions
In the present retrospective analysis of the PROWESS-
Shock trial database, we were unable to find a noticeable
positive impact from intravenous steroids for treatment of
septic shock at baseline either in patients randomized to
DrotAA or those randomized to placebo. These data could
support the premise that intravenous steroids should not be
systematically used in patients with septic shock; however
further research in a large RCT is warranted.
Key messages
 In the PROWESS-Shock trial, 49.5% of patients
received intravenous steroids for treatment of septic
shock at baseline.
 Septic shock patients treated with intravenous
steroids at baseline had more organ dysfunction,
higher APACHE II and SOFA scores, and needed
more vasopressors.
 After adjustment for treatment selection bias,
intravenous steroids for treatment of septic shockat baseline had no impact on 28-day and 90-day
mortality, either in patients randomized for
drotrecogin-alfa (activated) or placebo.
 The course of septic shock, assessed by the number
of vasopressor-free days (propensity-weighted), was
also similar in patients treated with and without
intravenous steroids.
 No significant interaction between intravenous
steroids and drotrecogin-alfa (activated) was found.
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